The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).
 
Tracy L Rose
Research Funding - Bristol-Myers Squibb; GeneCentric; Merck; Roche/Genentech; X4 Pharma
 
Michael Roger Harrison
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Fujifilm; Genentech; Janssen Oncology; Pfizer
Speakers' Bureau - Exelixis; Genentech
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
 
Allison Mary Deal
No Relationships to Disclose
 
Chelsea K. Osterman
No Relationships to Disclose
 
Sundhar Ramalingam
Honoraria - Bayer; Bayer
Research Funding - Exelixis
 
Young E. Whang
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst)
 
Blaine Y Brower
No Relationships to Disclose
 
Marc Bjurlin
No Relationships to Disclose
 
Angela B. Smith
Consulting or Advisory Role - Fergene; Merck; Photocure; Urogen pharma
 
Matthew E. Nielsen
Stock and Other Ownership Interests - Grand Rounds Health
 
Hung-Jui Tan
No Relationships to Disclose
 
Eric M. Wallen
No Relationships to Disclose
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Pfizer; Sanofi; Vizuri
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi; UroToday
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Exelixis; Genentech/Roche; MJH Life Sciences; Pacific Genuity
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Pfizer; Pharmacyclics; Sanofi; Seagen
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Sanofi/Aventis
Research Funding - Acerta Pharma (Inst); Astellas Pharma; Janssen (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; AstraZeneca; Genomic Health
 
Anthony Drier
No Relationships to Disclose
 
William Y. Kim
Stock and Other Ownership Interests - Abbvie; Amgen; Arvinas; BeiGene; Bristol-Myers Squibb; FibroGen; Fibrogen; G1 Therapeutics; Illumina; Johnson & Johnson; Kura Oncology; NantWorks; Oramed; Spectrum Pharmaceuticals
Honoraria - H3 Biomedicine; Takeda
Consulting or Advisory Role - Foundation Medicine; GeneCentric
Research Funding - Foundation Medicine; GeneCentric; Merck
Patents, Royalties, Other Intellectual Property - BASE47 bladder cancer subtype classifier
Travel, Accommodations, Expenses - H3 Biomedicine; Takeda
 
Matthew I. Milowsky
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Syndax (Inst)
Other Relationship - Asieris Pharmaceuticals (Inst)